



USTR: Response to Coronavirus Crisis

3/20/20



Office of the United States Trade Representative

FOR IMMEDIATE RELEASE

March 20, 2020

Contact: USTR Public & Media Affairs

media@ustr.eop.gov

USTR: Response to Coronavirus Crisis

Invites Public Comments to Identify Additional Products Potentially Helpful to U.S. Response
Washington, DC – Throughout the process of administering its Section 301 action to combat China's acts, policies and practices related to technology transfer, intellectual property, and innovation, the United States has prioritized health considerations, and it is taking additional action for that objective today.

In imposing tariffs on goods from China as part of the Section 301 action, the United States determined to not impose tariffs on certain critical products such as ventilators, oxygen masks, and nebulators. In addition, over the past year, USTR granted exclusions for a large number of health-related products. Notably, the imposition of tariffs on certain Chinese imports has not resulted in an overall decline in the availability of needed medical equipment and supplies. In fact, U.S. imports in 2019 of all critical medical and pharmaceutical products were up over 20 percent since 2017, before Section 301 tariffs were imposed.

Prior to the coronavirus outbreak, USTR and the Department of Health and Human Services worked together to ensure that critical medicines and other essential medical products were not subject to additional Section 301 tariffs, including parts needed for MRI devices, combined PET/CT scanners,

certain radiation therapy equipment, air purification equipment, and parts of homecare beds; sterile electrosurgical tools; digital clinical thermometers; and more.

Today, in an effort to keep current on developments in our national fight against the coronavirus pandemic, USTR has opened a docket for members of the public, businesses, and government agencies to submit comments if they believe further modifications to the 301 tariffs may be necessary. This comment process does not replace the current exclusion process and supplements that process. Submissions are limited to comments on products subject to the tariff actions and relevant to the medical response to the coronavirus.

Interested parties wishing to provide comments can do so [here](#).

###

The Office of the United States Trade Representative · Washington, D.C. 20508 · www.ustr.gov · 202-395-3230